Amazon One Medical GLP-1 programme launch reshapes weight-loss market
Amazon launched a national GLP-1 Management Programme on 21 April 2026, combining its One Medical primary care network, Amazon Pharmacy fulfilment, and Prime delivery logistics into a single end-to-end weight-loss offering. The move represents the first time Amazon has knitted together all three of its healthcare assets under one clinical programme, and the market reaction was immediate: shares in Hims & Hers fell roughly 6% on the announcement, while Walmart publicly defended its own GLP-1 platform.
The programme integrates GLP-1 prescribing directly into a patient's ongoing primary care relationship at One Medical, meaning the same clinician overseeing blood pressure, lab work, and metabolic health also manages weight-loss treatment. Pre-visit health screening, structured eligibility consultations, follow-up appointments, and integrated lab monitoring are all included. Amazon Pharmacy then handles dispensing, with same-day delivery available in nearly 3,000 US cities as of launch, and expansion to approximately 4,500 cities projected by year-end.
Pricing and access
Cash-pay pricing through Amazon Pharmacy is set at $149 per month for oral GLP-1 options — including the newly approved Foundayo — and $299 per month for injectables such as Wegovy and Zepbound. Insured patients may access oral formulations for as little as $25 per month where their plan covers weight-management GLP-1 therapy. Amazon says its pharmacy platform has generated more than $200 million in cumulative savings through automatic application of manufacturer coupon programmes.
One Medical membership, priced at $199 per year, is no longer a prerequisite for the GLP-1 programme. However, members avoid the $29–$49 per-request on-demand renewal charges that non-members face. Crucially, the on-demand telehealth pathway is limited to renewal of existing prescriptions for patients who have taken their medication within the past two weeks and are not requesting a dose change; new prescriptions require a scheduled consultation, with wait times varying by market.
Market context and competitive read-across
Amazon's entry fundamentally reframes the competitive landscape for GLP-1 telehealth. The incumbent model — built by companies such as Hims & Hers, Ro, and Noom Med — prioritised speed, often moving patients from online questionnaire to prescription within 24–48 hours with limited ongoing clinical involvement. Amazon is positioning against that model on depth of oversight rather than speed, treating obesity as a chronic condition requiring continuous medical supervision.
That is a meaningful strategic distinction, but it also creates real access gaps. One Medical operates physical clinics in roughly 20-plus US cities; patients outside those markets can access scheduled video consultations but lose the in-person primary care integration that differentiates the programme. New patients — those without an existing GLP-1 prescription — cannot use the on-demand telehealth pathway at all, and appointment availability for new scheduled consultations varies considerably by market.
The broader GLP-1 telehealth sector is operating under tightening regulatory conditions in 2026. The FDA issued warning letters to more than 30 platforms in early 2026 for GLP-1 marketing violations, and has drawn clearer lines around the compounded semaglutide and tirzepatide market that had grown rapidly during Wegovy and Zepbound supply shortages. Amazon's programme, built entirely around FDA-approved branded medications, is structurally insulated from that enforcement risk — a durable competitive advantage as regulatory scrutiny of compounding platforms intensifies.
For investors tracking the space, the key near-term question is whether Amazon's clinically integrated model attracts the insured, established-patient segment at scale, or whether the access friction for new and cash-pay patients keeps the larger addressable market with faster-moving telehealth-first competitors. A second watch point is how Novo Nordisk and Eli Lilly respond commercially to Amazon Pharmacy's growing leverage as a distribution channel for Wegovy and Zepbound respectively.